Gilbert C. Olini
Johnson & Johnson Pharmaceutical Research and Development
7 Papers
87 Citations
Gilbert C. Olini is an academic researcher from Johnson & Johnson Pharmaceutical Research and Development. The author has contributed to research in topics: Cytokine & Protein kinase A. The author has an hindex of 6, co-authored 7 publications.
Chat about Author
Papers
Imidazopyrimidines, potent inhibitors of p38 MAP kinase.
Kenneth C. Rupert,Henry James Robert,John H. Dodd,Scott A. Wadsworth,Druie Cavender,Gilbert C. Olini,Bohumila Fahmy,John Siekierka +7 more
TL;DR: A novel series of imidazopyrimidines have been discovered that potently inhibit p38 and suppress the production of TNF-alpha in vivo.
244
•Journal Article
RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase.
Scott Wadsworth,Druie Cavender,Scott Beers,P. Lalan,Peter H. Schafer,Elizabeth A. Malloy,Wei Wu,Bohumila Fahmy,Gilbert C. Olini,Janet E. Davis,J. L. Pellegrino-Gensey,Michael P. Wachter,John Siekierka +12 more
TL;DR: RWJ 67657 inhibited the enzymatic activity of recombinant p38alpha and beta, but not gamma or delta, in vitro and had no significant activity against a variety of other enzymes, based on these favorable biological properties.
182
6-Amino-2-(4-fluorophenyl)-4-methoxy-3- (4-pyridyl)-1H-pyrrolo[2,3-b]pyridine (RWJ 68354): A Potent and Selective p38 Kinase Inhibitor
J.R. Henry,K. C. Rupert,John H. Dodd,Ignatius J. Turchi,Scott Wadsworth,Druie Cavender,Bohumila Fahmy,Gilbert C. Olini,Janet E. Davis,J. L. Pellegrino-Gensey,Peter H. Schafer,John Siekierka +11 more
77
Targeting cytosolic phospholipase A2 by arachidonyl trifluoromethyl ketone prevents chronic inflammation in mice.
Ravi Malaviya,Justin Ansell,LeRoy Hall,Mila Fahmy,Rochelle L. Argentieri,Gilbert C. Olini,David W. Pereira,Runa Sur,Druie Cavender +8 more
TL;DR: Results suggest that a potent and specific chemical inhibitor of cPLA(2) may be useful for the treatment of chronic inflammatory diseases including rheumatoid arthritis, inflammatory bowel disease, psoriasis, and asthma.
36
Inhibitors of unactivated p38 MAP kinase.
James L. Bullington,Dennis C. Argentieri,Kristin M. Averill,Demetrius Carter,Druie Cavender,Bohumila Fahmy,Xiaodong Fan,Hall Daniel A,Geoffrey R. Heintzelman,Paul F. Jackson,Wai Ping Leung,Xun Li,Ping Ling,Gilbert C. Olini,Thomas Razler,Michael Reuman,Kenneth C. Rupert,Ronald K. Russell,John Siekierka,Scott A. Wadsworth,Russell Wolff,Bangping Xiang,Yue Mei Zhang +22 more
TL;DR: A novel series of pyridinylimidazole-based compounds are developed, which potently inhibit the p38 pathway by binding to unactivated p38 kinase and only weakly inhibiting activated p38 Kinase activity in vitro.
14